Analysts UBS upgrade Eli Lilly (LLY) target price to $1,550 and reiterate buy rating

Barclays has reiterated its overweight rating on Eli Lilly, increasing its price target from $1,400 to $1,550 per share, citing a growing volume opportunity despite ongoing pricing debates. Canaccord upgraded York Space Systems to buy, noting its Q3/26 revenues of $84.2 million, which were down 7.3% year-over-year, and an adjusted EBITDA loss of $27.6 million.

Jefferies initiated coverage on Yarrow Biosciences with a buy rating, highlighting its strong positioning in the Graves' disease market. JPMorgan maintained a neutral stance on Tesla but expressed optimism about its robotaxi operations, which they believe could validate the company's advantages in AI and vertical integration.

UBS upgraded Peabody Energy to buy, seeing a favorable risk/reward profile, while also upgrading Nucor to buy and raising its price target by 20% to $307 per share, citing a cash flow inflection.

Mizuho upgraded Viking Holdings ahead of its Q3 results, adjusting the target price to $120 from $82, while Goldman Sachs downgraded Yeti to neutral, lowering its price target to $41 from $57 due to reduced conviction in the stock. Other notable upgrades included Humana by RBC and Ingersoll Rand by Melius, both reflecting positive earnings potential and order recovery, respectively.

Overall, these analyst calls indicate a mixed outlook across various sectors, with some companies showing strong growth potential while others face challenges

Stocks in this article

Company Price Change Change % AI
Humana HUM.US 450.00 0.00 0.00% Buy
Ingersoll Rand IR.US 85.06 0.00 0.00% Hold
Eli Lilly LLY.US 1,443.50 0.00 0.00% Buy
Nucor NUE.US 251.73 0.00 0.00% Hold
Tesla TSLA.US 390.22 0.00 0.00% Hold
Viking Holdings VIK.US 89.87 0.00 0.00% Buy
Yeti Holdings YETI.US 39.42 0.00 0.00% Sell

StockGuide AI model context

Nucor · Hold · Risk: 70/100 · Potential: 60/100 · 2026-11-16

Viking Holdings · Buy · Risk: 39/100 · Potential: 70/100 · 2026-11-16

Yeti Holdings · Sell · Risk: 75/100 · Potential: 34/100 · 2026-11-16

More investing news